{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:28:11Z","timestamp":1793644091331,"version":"4.5.1"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["3400783"],"award-info":[{"award-number":["3400783"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Environmental Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.envres.2023.117132","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:25:13Z","timestamp":1694640313000},"page":"117132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"P1","title":["Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7633-9217","authenticated-orcid":false,"given":"Mahmood","family":"Fadaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dianat-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0295","authenticated-orcid":false,"given":"Elham","family":"Ghafouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsi","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Darvishali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Ghovvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khanahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Boshtam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooyan","family":"Makvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.envres.2023.117132_bib1","doi-asserted-by":"crossref","unstructured":"Al-Bahrani, M., Asavarut, P., Waramit, S., Suwan, K., Hajitou, A., 2022. bioRxiv. Transmorphic phage-guided systemic delivery of TNF\u03b1 gene for the treatment of human paediatric medulloblastoma.2022.10.18.512650.","DOI":"10.1101\/2022.10.18.512650"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/nano10030501","article-title":"Bacteriophage based biosensors: trends, outcomes and challenges","volume":"10","author":"Aliakbar Ahovan","year":"2020","journal-title":"Nanomaterials"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00284-021-02398-9","article-title":"Phage display technique as a tool for diagnosis and antibody selection for coronaviruses","volume":"78","author":"Anand","year":"2021","journal-title":"Curr. Microbiol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/08923973.2015.1027917","article-title":"Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study","volume":"37","author":"Asadi-Ghalehni","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/08923973.2015.1027917","article-title":"Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study","volume":"37","author":"Asadi-Ghalehni","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/antibiotics10080999","article-title":"Bacteriophage technology and modern medicine","volume":"10","author":"Azam","year":"2021","journal-title":"Antibiotics"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s12010-011-9365-1","article-title":"Phage displayed HBV core antigen with immunogenic activity","volume":"165","author":"Bahadir","year":"2011","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"10","key":"10.1016\/j.envres.2023.117132_bib8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/17425247.2014.927437","article-title":"Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems","volume":"11","author":"Bakhshinejad","year":"2014","journal-title":"Expet Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4236\/abb.2014.51008","article-title":"Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen","volume":"5","author":"Balcioglu","year":"2014","journal-title":"Adv. Biosci. Biotechnol."},{"key":"10.1016\/j.envres.2023.117132_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2018.12.013","article-title":"Phage-based vaccines","volume":"145","author":"Bao","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-8-37","article-title":"Killing cancer cells by targeted drug-carrying phage nanomedicines","volume":"8","author":"Bar","year":"2008","journal-title":"BMC Biotechnol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib12","first-page":"315","volume":"7","author":"Bedi","year":"2011","journal-title":"Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes"},{"issue":"20","key":"10.1016\/j.envres.2023.117132_bib13","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1016\/j.biomaterials.2012.03.054","article-title":"Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection","volume":"33","author":"Bhattarai","year":"2012","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib15","first-page":"466","volume":"32","author":"Carmody","year":"2021","journal-title":"Bacteriophage Capsid Modification by Genetic and Chemical Methods"},{"issue":"12","key":"10.1016\/j.envres.2023.117132_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms7120625","article-title":"Bacteriophage and the innate immune system: access and signaling","volume":"7","author":"Carroll-Portillo","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.envres.2023.117132_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2019.111482","article-title":"An affinity peptide-incorporated electrochemical biosensor for the detection of neutrophil gelatinase-associated lipocalin","volume":"142","author":"Cho","year":"2019","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.envres.2023.117132_bib18","first-page":"5825","article-title":"Chemical modulation of M13 bacteriophage and its functional opportunities for nanomedicine","volume":"9","author":"Chung","year":"2014","journal-title":"International journal of nanomedicine"},{"issue":"11","key":"10.1016\/j.envres.2023.117132_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/nbt.3011","article-title":"Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases","volume":"32","author":"Citorik","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00339-018-1637-y","article-title":"One-step production of phage\u2013silicon nanoparticles by PLAL as fluorescent nanoprobes for cell identification","volume":"124","author":"De Plano","year":"2018","journal-title":"Appl. Phys. A"},{"key":"10.1016\/j.envres.2023.117132_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.copbio.2020.11.002","article-title":"Phages in vaccine design and immunity; mechanisms and mysteries","volume":"68","author":"de Vries","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib23","first-page":"714","article-title":"Advances in the T7 phage display system","volume":"17","author":"Deng","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib24","first-page":"1","volume":"9","author":"Dizaj","year":"2014","journal-title":"A sight on the current nanoparticle-based gene delivery vectors"},{"key":"10.1016\/j.envres.2023.117132_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121763","article-title":"Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy","volume":"289","author":"Dong","year":"2022","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1021\/acs.nanolett.2c04279","article-title":"Engineered living bacteriophage-enabled self-adjuvanting hydrogel for remodeling tumor microenvironment and cancer therapy","volume":"23","author":"Dong","year":"2023","journal-title":"Nano Lett."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib27","first-page":"135","volume":"8","author":"Du","year":"2010","journal-title":"Targeted Drug Delivery to Hepatocarcinoma In vivo by Phage-Displayed Specific Binding PeptideTargeted Drug Delivery to Hepatocarcinoma by Peptide"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00284-014-0557-0","article-title":"Bacteriophage vehicles for phage display: biology, mechanism, and application","volume":"69","author":"Ebrahimizadeh","year":"2014","journal-title":"Curr. Microbiol."},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study","volume":"79","author":"Emery","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.envres.2023.117132_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.snb.2017.11.117","article-title":"Bacteriophages as biorecognition elements in capacitive biosensors: phage and host bacteria detection","volume":"258","author":"Ert\u00fcrk","year":"2018","journal-title":"Sensor. Actuator. B Chem."},{"key":"10.1016\/j.envres.2023.117132_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CCID.S10322","article-title":"Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency","volume":"4","author":"Farkas","year":"2011","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib32","first-page":"16","volume":"3","author":"Farokhzad","year":"2009","journal-title":"Impact of nanotechnology on drug delivery"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41423-020-00532-4","article-title":"Phages and their potential to modulate the microbiome and immunity","volume":"18","author":"Federici","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/vaccines8030504","article-title":"Bacteriophage-based vaccines: a potent approach for antigen delivery","volume":"8","author":"Gonz\u00e1lez-Mora","year":"2020","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib36","article-title":"Bacteriophage-based vaccines: a potent approach for antigen delivery","volume":"8","author":"Gonzalez-Mora","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.envres.2023.117132_bib37","article-title":"Evaluation of the immune response of a candidate phage-based vaccine against Rhipicephalus microplus (cattle tick)","volume":"13","author":"Gonz\u00e1lez-Mora","year":"2021","journal-title":"Pharmaceutics [Internet]"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00066-18","article-title":"Phage therapy in the postantibiotic era","volume":"32","author":"Gordillo Altamirano","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.envres.2023.117132_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.11.001","article-title":"Sensitizing pathogens to antibiotics using the CRISPR-Cas system","volume":"30","author":"Goren","year":"2017","journal-title":"Drug Resist. Updates"},{"issue":"1645","key":"10.1016\/j.envres.2023.117132_bib40","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1472-765X.2003.01400.x","article-title":"Genetically modified filamentous phage as bactericidal agents: a pilot study","volume":"37","author":"Hagens","year":"2003","journal-title":"Lett. Appl. Microbiol."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jviromet.2009.11.008","article-title":"Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine","volume":"163","author":"Hashemi","year":"2010","journal-title":"J. Virol Methods"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib43","first-page":"35","article-title":"Biosynthesized nanomaterials with antioxidant and antimicrobial properties","volume":"1","author":"Heidari","year":"2022","journal-title":"Materials Chemistry Horizons"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib44","doi-asserted-by":"crossref","DOI":"10.4161\/bact.24872","article-title":"What are the limitations on the wider therapeutic use of phage?","volume":"3","author":"Henein","year":"2013","journal-title":"Bacteriophage"},{"key":"10.1016\/j.envres.2023.117132_bib45","series-title":"Independent functions of viral protein and nucleic acid in growth of bacteriophage. Die Entdeckung der Doppelhelix","first-page":"121","author":"Hershey","year":"2017"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10142","article-title":"Phage display as a tool for vaccine and immunotherapy development","volume":"5","author":"Hess","year":"2020","journal-title":"Bioengineering & Translational Medicine"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10142","article-title":"Phage display as a tool for vaccine and immunotherapy development","volume":"5","author":"Hess","year":"2020","journal-title":"Bioeng Transl Med"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib48","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/bc300130z","article-title":"M13 bacteriophage display framework that allows sortase-mediated modification of surface-accessible phage proteins","volume":"23","author":"Hess","year":"2012","journal-title":"Bioconjugate Chem."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acs.analchem.0c03621","article-title":"Monoclonal antibody-based biosensor for point-of-care detection of type III secretion system expressing pathogens","volume":"93","author":"Hillman","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.envres.2023.117132_bib50","first-page":"1","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies","volume":"15","author":"Hossen","year":"2019","journal-title":"A review"},{"key":"10.1016\/j.envres.2023.117132_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtadv.2021.100168","article-title":"Detection of a single circulating tumor cell using a genetically engineered antibody-like phage nanofiber probe","volume":"12","author":"Hou","year":"2021","journal-title":"Materials Today Advances"},{"key":"10.1016\/j.envres.2023.117132_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2022.132811","article-title":"Gold nanoparticles-decorated M13 phage SPR probe for dual detection of antigen biomarkers in serum","volume":"374","author":"Hou","year":"2023","journal-title":"Sensor. Actuator. B Chem."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00013-20","article-title":"Stable neutralization of a virulence factor in bacteria using temperate phage in the mammalian gut","volume":"5","author":"Hsu","year":"2020","journal-title":"mSystems"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib54","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/adhm.201500930","article-title":"Genetically engineered virus nanofibers as an efficient vaccine for preventing fungal infection","volume":"5","author":"Huai","year":"2016","journal-title":"Adv. Healthcare Mater."},{"issue":"28","key":"10.1016\/j.envres.2023.117132_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201901233","article-title":"M13 virus\u2010based framework for high fluorescence enhancement","volume":"15","author":"Huang","year":"2019","journal-title":"Small"},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib56","first-page":"482","article-title":"Romiplostim (nplate), a treatment option for immune (idiopathic) thrombocytopenic purpura","volume":"34","author":"Hubulashvili","year":"2009","journal-title":"PT"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcjo.2014.05.010","article-title":"Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration","volume":"49","author":"Iordanous","year":"2014","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.envres.2023.117132_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jelechem.2016.05.019","article-title":"Bacteriophages in electrochemistry: a review","volume":"779","author":"Janczuk","year":"2016","journal-title":"J. Electroanal. Chem."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(02)00682-8","article-title":"Peptide-targeted PEG-liposomes in anti-angiogenic therapy","volume":"254","author":"Janssen","year":"2003","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1016\/j.envres.2023.117132_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jim.2004.09.011","article-title":"Direct fluorochrome labeling of phage display library clones for studying binding specificities: applications in flow cytometry and fluorescence microscopy","volume":"295","author":"Jaye","year":"2004","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib61","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.7150\/thno.49781","article-title":"A blood circulation-prolonging peptide anchored biomimetic phage-platelet hybrid nanoparticle system for prolonged blood circulation and optimized anti-bacterial performance","volume":"11","author":"Jin","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biori.2017.10.001","article-title":"The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches","volume":"1","author":"Jorge","year":"2017","journal-title":"Biotechnology Research and Innovation"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib63","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1080\/10717544.2017.1410259","article-title":"Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles","volume":"24","author":"Ju","year":"2017","journal-title":"Drug Deliv."},{"issue":"Pt A","key":"10.1016\/j.envres.2023.117132_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.addr.2016.03.003","article-title":"Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos","volume":"106","author":"Karimi","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.envres.2023.117132_bib65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.addr.2016.03.003","article-title":"Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos","volume":"106","author":"Karimi","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.envres.2023.117132_bib66","series-title":"Expanding the Chemical Diversity of M13 Bacteriophage","first-page":"2777","author":"Kay","year":"2022"},{"issue":"11","key":"10.1016\/j.envres.2023.117132_bib67","first-page":"4056","volume":"105","author":"Kehoe","year":"2005","journal-title":"Filamentous phage display in the new millennium"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib68","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-020-16731-6","article-title":"Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria","volume":"11","author":"Kiga","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00705-003-0192-8","article-title":"Expression of a Foot-and-mouth disease virus immunodominant epitope by a filamentous bacteriophage vector","volume":"149","author":"Kim","year":"2004","journal-title":"Arch. Virol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/pbc.23312","article-title":"Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)","volume":"58","author":"Klaassen","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib71","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/acs.nanolett.5b01943","article-title":"Engineered phagemids for nonlytic, targeted antibacterial therapies","volume":"15","author":"Krom","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.envres.2023.117132_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.609459","article-title":"Futuristic non-antibiotic therapies to combat antibiotic resistance: a review","volume":"12","author":"Kumar","year":"2021","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10238-008-0027-8","article-title":"Bacteriophage interactions with phagocytes and their potential significance in experimental therapy","volume":"9","author":"Kurzepa","year":"2009","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109930","article-title":"Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome","volume":"37","author":"Lam","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-virology-092917-043544","article-title":"Phage-based applications in synthetic biology","volume":"5","author":"Lemire","year":"2018","journal-title":"Annual Review of Virology"},{"issue":"6","key":"10.1016\/j.envres.2023.117132_bib76","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12275-019-8686-6","article-title":"Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018","volume":"57","author":"Lemon","year":"2019","journal-title":"J. Microbiol."},{"issue":"21","key":"10.1016\/j.envres.2023.117132_bib78","first-page":"4943","volume":"32","author":"Li","year":"2011","journal-title":"Targeting the brain with PEG\u2013PLGA nanoparticles modified with phage-displayed peptides"},{"issue":"13","key":"10.1016\/j.envres.2023.117132_bib79","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.7150\/ijbs.60551","article-title":"A combination therapy of Phages and Antibiotics: two is better than one","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.envres.2023.117132_bib77","doi-asserted-by":"crossref","unstructured":"Li, S, Lakshmanan, RS, Petrenko, VA, Chin, BA, n.d.. Phage-based pathogen biosensors. Phage Nanobiotechnol. 101\u2013155 2011.","DOI":"10.1039\/BK9780854041848-00101"},{"key":"10.1016\/j.envres.2023.117132_bib80","series-title":"Silencing of Antibiotic Resistance in E. coli with Engineered Phage Bearing Small Regulatory RNAs","first-page":"1003","author":"Libis","year":"2014"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: an alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Therapeut"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib82","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/v13071268","article-title":"The safety and toxicity of phage therapy: a review of animal and clinical studies","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/pharmaceutics14020427","article-title":"Phages against pathogenic bacterial biofilms and biofilm-based infections: a review","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Loc-Carrillo","year":"2011","journal-title":"Bacteriophage"},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib85","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/mmi.14187","article-title":"The fascinating biology behind phage display: filamentous phage assembly","volume":"111","author":"Loh","year":"2019","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.envres.2023.117132_bib86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cimid.2019.05.004","article-title":"Immunological properties of the SLLTEVET epitope of Influenza A virus in multiple display on filamentous M13 phage","volume":"65","author":"Lotfi","year":"2019","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"issue":"12","key":"10.1016\/j.envres.2023.117132_bib87","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1073\/pnas.0800442106","article-title":"Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy","volume":"106","author":"Lu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.envres.2023.117132_bib88","article-title":"Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib89","article-title":"Construction of a recombinant phage-vaccine capable of reducing the growth rate of an established LL2 tumor model","volume":"17","author":"Majid","year":"2018","journal-title":"Iran. J. Allergy, Asthma Immunol."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vetimm.2003.12.009","article-title":"Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis","volume":"99","author":"Manoutcharian","year":"2004","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"11","key":"10.1016\/j.envres.2023.117132_bib91","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1021\/acschembio.5b00717","article-title":"Phage display technology in biomaterials engineering: progress and opportunities for applications in regenerative medicine","volume":"11","author":"Martins","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00253-021-11713-0","article-title":"Current view on novel vaccine technologies to combat human infectious diseases","volume":"106","author":"Mati\u0107","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tips.2018.12.005","article-title":"Phage display: an overview in context to drug discovery","volume":"40","author":"Mimmi","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1574-6968.2009.01620.x","article-title":"Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli","volume":"296","author":"Moradpour","year":"2009","journal-title":"FEMS Microbiol. Lett."},{"issue":"23","key":"10.1016\/j.envres.2023.117132_bib95","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2008.03.042","article-title":"Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis","volume":"26","author":"Morales","year":"2008","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.envres.2023.117132_bib96","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2008.03.042","article-title":"Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis","volume":"26","author":"Morales","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.envres.2023.117132_bib97","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3389\/fimmu.2019.02776","article-title":"Editorial: reverse vaccinology","volume":"10","author":"Moxon","year":"2019","journal-title":"Front. Immunol."},{"issue":"10325","key":"10.1016\/j.envres.2023.117132_bib98","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00052-20","article-title":"Are there 1031 virus particles on earth, or more, or fewer?","volume":"202","author":"Mushegian","year":"2020","journal-title":"J. Bacteriol."},{"issue":"17","key":"10.1016\/j.envres.2023.117132_bib100","first-page":"1963","volume":"5","author":"Ngweniform","year":"2009","journal-title":"Self\u2010Assembly of Drug\u2010Loaded Liposomes on Genetically Engineered Target\u2010Recognizing M13 Phage: A Novel Nanocarrier for Targeted Drug Delivery"},{"issue":"35","key":"10.1016\/j.envres.2023.117132_bib101","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1002\/anie.201404761","article-title":"Advancing the drug discovery and development process","volume":"53","author":"Nicolaou","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/bios12010030","article-title":"Advances in the development of phage-based probes for detection of bio-species","volume":"12","author":"Paramasivam","year":"2022","journal-title":"Biosensors"},{"key":"10.1016\/j.envres.2023.117132_bib103","doi-asserted-by":"crossref","DOI":"10.34133\/bdr.0004","article-title":"Phages and nanotechnology: new insights against multidrug-resistant bacteria","volume":"5","author":"Pardo-Freire","year":"2023","journal-title":"BioDesign Research"},{"issue":"10","key":"10.1016\/j.envres.2023.117132_bib104","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.3390\/s20102775","article-title":"Surface display technology for biosensor applications: a review","volume":"20","author":"Park","year":"2020","journal-title":"Sensors"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1021\/acsnano.8b06395","article-title":"Rapid colorimetric detection of bacterial species through the capture of gold nanoparticles by chimeric phages","volume":"13","author":"Peng","year":"2018","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib106","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1073\/pnas.1913234117","article-title":"Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric phages","volume":"117","author":"Peng","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib107","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1021\/acsnano.2c00048","article-title":"Treatment of wound infections in a mouse model using Zn2+-releasing phage bound to gold nanorods","volume":"16","author":"Peng","year":"2022","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.envres.2023.117132_bib108","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/v10060311","article-title":"Landscape phage: evolution from phage display to nanobiotechnology","volume":"10","author":"Petrenko","year":"2018","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib109","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/v11090785","article-title":"Combinatorial avidity selection of mosaic landscape phages targeted at breast cancer cells\u2014an alternative mechanism of directed molecular evolution","volume":"11","author":"Petrenko","year":"2019","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.envres.2023.117132_bib110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5694\/mja2.50355","article-title":"Phage therapy for severe bacterial infections: a narrative review","volume":"212","author":"Petrovic Fabijan","year":"2020","journal-title":"Med. J. Aust."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002119","article-title":"Translating phage therapy into the clinic: recent accomplishments but continuing challenges","volume":"21","author":"Petrovic Fabijan","year":"2023","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/MMBR.00069-15","article-title":"Genetically engineered phages: a review of advances over the last decade","volume":"80","author":"Pires","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"16","key":"10.1016\/j.envres.2023.117132_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168937","article-title":"Interactions of bacteriophages with animal and human organisms-safety issues in the light of phage therapy","volume":"22","author":"Podlacha","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.envres.2023.117132_bib114","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-virology-091919-074551","article-title":"Bacteriophages and the immune system","volume":"8","author":"Popescu","year":"2021","journal-title":"Annual Review of Virology"},{"issue":"13","key":"10.1016\/j.envres.2023.117132_bib115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12859-018-2482-x","article-title":"Exploitation of reverse vaccinology and immunoinformatics as promising platform for genome-wide screening of new effective vaccine candidates against Plasmodium falciparum","volume":"19","author":"Pritam","year":"2019","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.envres.2023.117132_bib116","article-title":"Interactions between bacteriophages and eukaryotic cells","volume":"2020","author":"Putra","year":"2020","journal-title":"Scientifica (Cairo)"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib117","article-title":"Phage Therapy: a modern tool to control bacterial infections","volume":"28","author":"Qadir","year":"2015","journal-title":"Pak. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.envres.2023.117132_bib118","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7560.1000194","article-title":"Reverse vaccinology: basics and applications","volume":"4","author":"Rajkumar Soni","year":"2013","journal-title":"J. Vaccines Vaccin."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib119","first-page":"51","article-title":"Filamentous bacteriophage: biology, phage display and nanotechnology applications","volume":"13","author":"Rakonjac","year":"2011","journal-title":"Curr. Issues Mol. Biol."},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.apjtb.2017.06.001","article-title":"An overview on application of phage display technique in immunological studies","volume":"7","author":"Rami","year":"2017","journal-title":"Asian Pac. J. Trop. Biomed."},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/CDLI.10.4.536-541.2003","article-title":"Expression of a 28-kilodalton glutathione S-transferase antigen of schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential","volume":"10","author":"Rao Kakuturu","year":"2003","journal-title":"Clin. Vaccine Immunol."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib122","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS microbiology"},{"key":"10.1016\/j.envres.2023.117132_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2020.129227","article-title":"Rapid detection of bacterial pathogens in blood through engineered phages-beads and integrated Real-Time PCR into MicroChip","volume":"329","author":"Rizzo","year":"2021","journal-title":"Sensor. Actuator. B Chem."},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib124","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/antibiotics8030138","article-title":"Bacteriophages as alternatives to antibiotics in clinical care","volume":"8","author":"Romero-Calle","year":"2019","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib125","doi-asserted-by":"crossref","first-page":"ysy002","DOI":"10.1093\/synbio\/ysy002","article-title":"Cell-free TXTL synthesis of infectious bacteriophage T4 in a single test tube reaction","volume":"3","author":"Rustad","year":"2018","journal-title":"Synth Biol (Oxf)."},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91997-4","article-title":"Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches","volume":"11","author":"Sanami","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.envres.2023.117132_bib127","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2680160","article-title":"Fundamentals and methods for T- and B-cell epitope prediction","volume":"2017","author":"Sanchez-Trincado","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.envres.2023.117132_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2019.111794","article-title":"Non-lytic M13 phage-based highly sensitive impedimetric cytosensor for detection of coliforms","volume":"148","author":"Sedki","year":"2020","journal-title":"Biosens. Bioelectron."},{"issue":"37","key":"10.1016\/j.envres.2023.117132_bib129","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1016\/j.vaccine.2013.05.044","article-title":"Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant","volume":"31","author":"Segura-Vel\u00e1zquez","year":"2013","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.envres.2023.117132_bib130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00534-18","article-title":"Efficient genome engineering of a virulent Klebsiella bacteriophage using CRISPR-Cas9","volume":"92","author":"Shen","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.envres.2023.117132_bib131","series-title":"Phage Display in Biotechnology and Drug Discovery","author":"Sidhu","year":"2015"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib132","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12033-019-00156-8","article-title":"Phage display libraries: from binders to targeted drug delivery and human therapeutics","volume":"61","author":"Sioud","year":"2019","journal-title":"Mol. Biotechnol."},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib133","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1473-3099(20)30069-4","article-title":"Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study","volume":"20","author":"Skoura","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib134","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41570-019-0159-2","article-title":"Methods for generating and screening libraries of genetically encoded cyclic peptides in drug discovery","volume":"4","author":"Sohrabi","year":"2020","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.envres.2023.117132_bib135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.fsi.2016.05.027","article-title":"Injected phage-displayed-VP28 vaccine reduces shrimp Litopenaeus vannamei mortality by white spot syndrome virus infection","volume":"55","author":"Sol\u00eds-Lucero","year":"2016","journal-title":"Fish Shellfish Immunol."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib136","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.envres.2023.117132_bib137","first-page":"31","author":"Sun","year":"2021","journal-title":"Engineered nanoparticles for drug delivery in cancer therapy"},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib138","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/anie.201606181","article-title":"Phage\u2010enabled nanomedicine: from probes to therapeutics in precision medicine","volume":"56","author":"Sunderland","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"issue":"37","key":"10.1016\/j.envres.2023.117132_bib139","doi-asserted-by":"crossref","first-page":"18571","DOI":"10.1073\/pnas.1906653116","article-title":"Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer","volume":"116","author":"Suwan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-020-01263-6","article-title":"Ramucirumab: a review in hepatocellular carcinoma","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.envres.2023.117132_bib141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/IDR.S234353","article-title":"How phages overcome the challenges of drug resistant bacteria in clinical infections","author":"Taati Moghadam","year":"2020","journal-title":"Infect. Drug Resist."},{"issue":"33","key":"10.1016\/j.envres.2023.117132_bib142","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v20.i33.11650","article-title":"Phage display creates innovative applications to combat hepatitis B virus","volume":"20","author":"Tan","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"10","key":"10.1016\/j.envres.2023.117132_bib143","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1021\/acssynbio.7b00179","article-title":"Engineering of bacteriophage T4 genome using CRISPR-Cas9","volume":"6","author":"Tao","year":"2017","journal-title":"ACS Synth. Biol."},{"issue":"10039","key":"10.1016\/j.envres.2023.117132_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib145","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.envres.2023.117132_bib146","unstructured":"The United States Food and Drug Administration\/https:\/\/www.fda.gov\/[."},{"key":"10.1016\/j.envres.2023.117132_bib147","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/IDR.S290093","article-title":"Bacteriophage\u2013a promising alternative measure for bacterial biofilm control","author":"Tian","year":"2021","journal-title":"Infect. Drug Resist."},{"issue":"15","key":"10.1016\/j.envres.2023.117132_bib148","first-page":"8786","volume":"98","author":"Torchilin","year":"2001","journal-title":"TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors"},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib149","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1021\/acsnano.1c08720","article-title":"Phage particles of controlled length and genome for in vivo targeted glioblastoma imaging and therapeutic delivery","volume":"16","author":"Tsedev","year":"2022","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib150","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1021\/acsnano.1c08720","article-title":"Phage particles of controlled length and genome for in vivo targeted glioblastoma imaging and therapeutic delivery","volume":"16","author":"Tsedev","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.envres.2023.117132_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/v11010010","article-title":"Interactions between bacteriophage, bacteria, and the mammalian immune system","volume":"11","author":"Van Belleghem","year":"2018","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib152","first-page":"951","volume":"5","author":"Vargason","year":"2021","journal-title":"The evolution of commercial drug delivery technologies"},{"issue":"7","key":"10.1016\/j.envres.2023.117132_bib153","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012435","article-title":"Biological foundations of successful bacteriophage therapy","volume":"14","author":"Venturini","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004018","article-title":"Synthetic biology: emerging concepts to design and advance adeno\u2010associated viral vectors for gene therapy","volume":"8","author":"Wagner","year":"2021","journal-title":"Adv. Sci."},{"issue":"20\u201322","key":"10.1016\/j.envres.2023.117132_bib155","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/S0264-410X(00)00561-2","article-title":"Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine","volume":"19","author":"Wan","year":"2001","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib156","first-page":"563","volume":"5","author":"Wang","year":"2010","journal-title":"Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein"},{"issue":"8","key":"10.1016\/j.envres.2023.117132_bib157","first-page":"597","volume":"19","author":"Wang","year":"2011","journal-title":"In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein"},{"issue":"12","key":"10.1016\/j.envres.2023.117132_bib158","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-14-0052","article-title":"Paclitaxel-loaded PEG-PE\u2013based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce TumorsAntitumor by phage protein\u2013targeting micellar paclitaxel","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib159","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nano.2013.08.009","article-title":"Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein","volume":"10","author":"Wang","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.envres.2023.117132_bib160","series-title":"Vaccines for Invasive Fungal Infections: Methods and Protocols","first-page":"225","article-title":"Vaccination with phage-displayed antigenic epitope","author":"Wang","year":"2017"},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1871520618666181029140814","article-title":"Phage display technology and its applications in cancer immunotherapy","volume":"19","author":"Wang","year":"2019","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"16","key":"10.1016\/j.envres.2023.117132_bib162","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14164054","article-title":"HER2-Displaying M13 bacteriophages induce therapeutic immunity against breast cancer","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib163","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4236\/aim.2021.113013","article-title":"Phage display technology, phage display system, antibody library, prospects and challenges","volume":"11","author":"Wen","year":"2021","journal-title":"Adv. Microbiol."},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib164","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1128\/AAC.47.4.1301-1307.2003","article-title":"Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections","volume":"47","author":"Westwater","year":"2003","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"10.1016\/j.envres.2023.117132_bib165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.envres.2023.117132_bib166","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.envres.2023.117132_bib167","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ijc.10260","article-title":"Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anti-tumor immunity in murine p815 model","volume":"98","author":"Wu","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.envres.2023.117132_bib168","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.vaccine.2004.12.018","article-title":"Development of a phage displayed disulfide-stabilized Fv fragment vaccine against Vibrio anguillarum","volume":"23","author":"Xia","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.envres.2023.117132_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtadv.2020.100122","article-title":"Naked-eye counting of pathogenic viruses by phage-gold nanobiomaterials as probes","volume":"10","author":"Xu","year":"2021","journal-title":"Materials Today Advances"},{"issue":"30","key":"10.1016\/j.envres.2023.117132_bib170","first-page":"7738","volume":"31","author":"Yoo","year":"2010","journal-title":"Targeted delivery of chitosan nanoparticles to Peyer\u2019s patch using M cell-homing peptide selected by phage display technique"},{"issue":"4","key":"10.1016\/j.envres.2023.117132_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103645","article-title":"T7 phage as an emerging nanobiomaterial with genetically tunable target specificity","volume":"9","author":"Yue","year":"2022","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.envres.2023.117132_bib172","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.envres.2023.117132_bib173","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","volume":"23","author":"Zylberberg","year":"2016","journal-title":"Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape"}],"container-title":["Environmental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013935123019369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013935123019369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:36:45Z","timestamp":1793641005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013935123019369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":173,"alternative-id":["S0013935123019369"],"URL":"https:\/\/doi.org\/10.1016\/j.envres.2023.117132","relation":{},"ISSN":["0013-9351"],"issn-type":[{"value":"0013-9351","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy","name":"articletitle","label":"Article Title"},{"value":"Environmental Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.envres.2023.117132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117132"}}